The possibility that FGF10, via PPAR-γ signaling, can drive reinforcement of the lipogenic phenotype at the expense of the myogenic phenotype raises the potential that FGF10-based therapies could be beneficial in combating idiopathic pulmonary fibrosis (IPF) and/or COVID-19 related pulmonary fibrosis. This evidence concerns the gene FGF10 and COVID-19.